SRTS vs. NVCN, STIM, APYX, NPCE, LYRA, LUCD, BVS, AKLI, PDEX, and RVP
Should you be buying Sensus Healthcare stock or one of its competitors? The main competitors of Sensus Healthcare include Neovasc (NVCN), Neuronetics (STIM), Apyx Medical (APYX), NeuroPace (NPCE), Lyra Therapeutics (LYRA), Lucid Diagnostics (LUCD), Bioventus (BVS), Akili (AKLI), Pro-Dex (PDEX), and Retractable Technologies (RVP). These companies are all part of the "surgical & medical instruments" industry.
Sensus Healthcare vs.
Neovasc (NASDAQ:NVCN) and Sensus Healthcare (NASDAQ:SRTS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, community ranking, institutional ownership, dividends and earnings.
Neovasc received 223 more outperform votes than Sensus Healthcare when rated by MarketBeat users. However, 68.63% of users gave Sensus Healthcare an outperform vote while only 65.03% of users gave Neovasc an outperform vote.
Sensus Healthcare has a net margin of 54.44% compared to Neovasc's net margin of -1,077.37%. Sensus Healthcare's return on equity of 25.55% beat Neovasc's return on equity.
Neovasc has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500. Comparatively, Sensus Healthcare has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.
Sensus Healthcare has a consensus price target of $16.83, indicating a potential upside of 234.66%. Given Sensus Healthcare's stronger consensus rating and higher probable upside, analysts plainly believe Sensus Healthcare is more favorable than Neovasc.
In the previous week, Neovasc had 1 more articles in the media than Sensus Healthcare. MarketBeat recorded 3 mentions for Neovasc and 2 mentions for Sensus Healthcare. Sensus Healthcare's average media sentiment score of 1.89 beat Neovasc's score of 0.41 indicating that Sensus Healthcare is being referred to more favorably in the news media.
1.6% of Neovasc shares are owned by institutional investors. Comparatively, 36.3% of Sensus Healthcare shares are owned by institutional investors. 0.5% of Neovasc shares are owned by insiders. Comparatively, 16.4% of Sensus Healthcare shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Sensus Healthcare has higher revenue and earnings than Neovasc. Neovasc is trading at a lower price-to-earnings ratio than Sensus Healthcare, indicating that it is currently the more affordable of the two stocks.
Summary
Sensus Healthcare beats Neovasc on 14 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SRTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Sensus Healthcare Competitors List